Healthcare · NYSE/NASDAQ: JNJ
Johnson & Johnson
Drug Manufacturers
Market Cap $420.00B
Verdict: High
Quality Scores
Multi-Bagger
65/100
Compounder Quality
89/100
Management Credibility
84/100
Governance
85/100
Cash Flow Quality
95/100
AI Summary
Johnson & Johnson (JNJ) remains a global healthcare titan, recently undergoing a massive structural shift with the spinoff of its Kenvue consumer health division to focus on high-margin Pharmaceuticals (Innovative Medicine) and MedTech. The 10-year data reveals a company capable of generating massive operating cash flow, consistently exceeding $20 billion annually despite significant litigation headwinds. While net income shows volatility due to one-time charges related to talc litigation and tax adjustments, the underlying core business remains exceptionally robust. The balance sheet is…
Top Opportunities
- Consistent Cash Flow from Operations over 10 years
- Successful spinoff of Consumer Health (Kenvue) to unlock value
- Robust Pharmaceutical pipeline with multiple blockbusters
Top Risks
- Significant Talc-related litigation liabilities
- Increasing Long-Term Debt levels in recent years
- Opioid litigation settlements impacting one-time costs
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.